Ulcerative Colitis Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects, and Future Ulcerative Colitis Pipeline Landscape

Ulcerative Colitis Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects, and Future Ulcerative Colitis Pipeline Landscape

DelveInsight’s, “Ulcerative Colitis Pipeline Insight, 2022,” report provides comprehensive insights about 110+ companies and 110+ pipeline drugs in Ulcerative Colitis (UC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. In the Ulcerative Colitis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ulcerative Colitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Recent Developmental Activities in the Ulcerative Colitis Pipeline

  • Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin 23. Mirikizumab is being studied for the treatment of immune-mediated diseases, including ulcerative colitis and Crohn’s disease.
  • Risankizumab  is an antagonistic anti-CD40 antibody. The CD40-CD40L pathway may play a major role in immune disease such as lupus nephritis, Crohn’s disease and ulcerative colitis.
  • Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. It is being investigated for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn’s disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata

 

Key takeaways from the Ulcerative Colitis Pipeline Insight Report

  • DelveInsight’s analysis presents the Ulcerative Colitis Pipeline with 110+ active players in the domain investigating 110+ pipeline therapies.
  • The leading Ulcerative Colitis Companies are working such as Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio, Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma, Seres Therapeutics, Abivax, Genentech, I-Mab Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu Biologics, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular Transport, AbGenomics International, Protalix BioTherapeutics, LTT Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE Immunotherapeutics, Bridge Biotherapeutics, Mitsubishi Tanabe Pharma, Sterna Biologicals, Mesoblast, and others.
  • Promising Ulcerative Colitis Pipeline therapies such as ABX464, adalimumab, Budesonide MMX® 6 mg, tralokinumab, BBT-401-1S, Filgotinib, PTM filgotinib, Mesalazine, and others.
  • The Ulcerative Colitis Companies and academics are working to assess challenges and seek opportunities that could influence Ulcerative Colitis R&D. The therapies under development are focused on novel approaches to treat/improve Ulcerative Colitis.

 

Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ Ulcerative Colitis Pipeline Outlook Report

 

Ulcerative Colitis Overview

Ulcerative colitis is a chronic disease of the large intestine, in which the lining of the colon become inflamed and develops tiny open sores or ulcers. Those ulcers produce pus and mucous, which causes abdominal pain. It usually begins in the rectum and spreads upwards. The inflammation causes bowel to move its content rapidly and empty frequently. Ulcerative colitis begins gradually and become worse over the period of time. Ulcerative colitis also known as inflammatory bowel disease. Ulcerative colitis symptoms range from mild to severe and varies among affected people. The predominant symptoms in ulcerative colitis is diarrhea, which can be associated with the discharge of blood in the stool.

 

Ulcerative Colitis Pipeline Insight Report

In the Ulcerative Colitis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ulcerative Colitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Ulcerative Colitis Emerging Drugs

  • Mirikizumab: Eli Lilly and Company
  • Risankizumab: AbbVie
  • Etrasimod: Pfizer

 

Request for Sample to know more @ Ulcerative Colitis Pipeline Analysis, Key Companies, and Futuristic Trends

 

Ulcerative Colitis Pipeline Therapeutics Assessment

There are approx. 110+ key companies which are developing the therapies for Ulcerative Colitis. The companies which have their Ulcerative Colitis drug candidates in the most advanced stage, i.e. Preregistration include, Gilead Sciences.

 

Ulcerative Colitis Pipeline Segmentation

The Ulcerative Colitis Pipeline report proffers an integral view of the Ulcerative Colitis emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

 

Scope of the Ulcerative Colitis Pipeline Report

  • Coverage- Global
  • Ulcerative Colitis CompaniesEli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio, Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma, Seres Therapeutics, Abivax, Genentech, I-Mab Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu Biologics, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular Transport, AbGenomics International, Protalix BioTherapeutics, LTT Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE Immunotherapeutics, Bridge Biotherapeutics, Mitsubishi Tanabe Pharma, Sterna Biologicals, Mesoblast, and others
  • Ulcerative Colitis Pipeline therapies- ABX464, adalimumab, Budesonide MMX® 6 mg, tralokinumab, BBT-401-1S, Filgotinib, PTM filgotinib, Mesalazine, and others

 

Table of Content

  1. Introduction
  2. Ulcerative Colitis Executive Summary
  3. Ulcerative Colitis: Overview
  4. Ulcerative Colitis Pipeline Therapeutics
  5. Ulcerative Colitis Therapeutic Assessment
  6. Ulcerative Colitis– DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Ulcerative Colitis Collaboration Deals
  9. Late Stage Products (Preregistration)
  10. Mirikizumab: Eli Lilly and Company
  11. Drug profiles in the detailed report…..
  12. Late Stage Products (Phase III)
  13. Upadacitinib: AbbVie
  14. Drug profiles in the detailed report…..
  15. Mid Stage Products (Phase II/III)
  16. TD-1473: Theravance Biopharma
  17. Drug profiles in the detailed report…..
  18. Mid Stage Products (Phase II)
  19. LYC-30937: Lycera
  20. Drug profiles in the detailed report…..
  21. Early Stage Products (Phase I/II)
  22. Remestemcel-L: Mesoblast
  23. Drug profiles in the detailed report…..
  24. Early Stage Products (Phase I)
  25. OPL-002: Oppilan Pharma
  26. Drug profiles in the detailed report…..
  27. IND Stage Products
  28. SVT-1A710: Servatus
  29. Drug profiles in the detailed report…..
  30. Preclinical Stage Products
  31. ATH-001: Athos Therapeutics
  32. Drug profiles in the detailed report…..
  33. Discovery Stage Products
  34. NM 001: NuMedii
  35. Inactive Products
  36. Ulcerative Colitis Key Companies
  37. Ulcerative Colitis Key Products
  38. Ulcerative Colitis- Unmet Needs
  39. Ulcerative Colitis- Market Drivers and Barriers
  40. Ulcerative Colitis- Future Perspectives and Conclusion
  41. Ulcerative Colitis Analyst Views
  42. Ulcerative Colitis Key Companies
  43. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Ulcerative Colitis (UC) drugs?
  • How many Ulcerative Colitis (UC) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ulcerative Colitis (UC)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ulcerative Colitis (UC) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Ulcerative Colitis (UC) and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Discover more about the scope of the report @ Ulcerative Colitis Clinical Trials Analysis Report

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/